Multinational phase 2 trial of first-line dabrafenib plus trametinib versus standard chemotherapy for pediatric glioma with BRAF V600 mutations

In pediatric low-grade glioma, the BRAF V600E mutation has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy. A multinational randomized phase 2 trial now compared first-line dabrafenib plus trametinib versus carboplatin plus vincristine for pediatric low-grade glioma with BRAF V600 mutations. The study found that dabrafenib plus trametinib resulted in significantly more responses, longer progression-free survival, and a better safety profile than standard chemotherapy (quick take video summary).